MorphoSys is headquartered near Munich, Germany and has a wholly owned subsidiary, MorphoSys US Inc, in Boston MA in the US.
| FactSnippet No. 1,602,181 |
11 Facts About MorphoSys
2.
MorphoSys has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates.
| FactSnippet No. 1,602,182 |
3.
MorphoSys has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases.
| FactSnippet No. 1,602,183 |
4.
MorphoSys AG is listed on the Frankfurt Stock Exchange and on the US Nasdaq stock exchange.
| FactSnippet No. 1,602,184 |
5.
In 1999, MorphoSys listed on the Frankfurt Stock Exchange under the ticker symbol "MOR".
| FactSnippet No. 1,602,185 |
6.
In 2010, MorphoSys signed a license agreement with Xencor Inc for MOR208.
| FactSnippet No. 1,602,186 |
7.
In March 2020, MorphoSys announced that the FDA had accepted the Biologics License Application for filing and granted priority review for tafasitamab, setting a Prescription Drug User Fee Act goal date of August 30,2020.
| FactSnippet No. 1,602,187 |
8.
In 2017, MorphoSys entered into a regional licensing agreement with I-Mab Biopharma to develop and commercialize Felzartamab in Greater China.
| FactSnippet No. 1,602,188 |
9.
MorphoSys has discovered a number of antibody technologies that are use for drug development.
| FactSnippet No. 1,602,189 |
10.
MorphoSys' main technology is HuCAL, which is a collection of more than ten billion fully human antibodies in the form of a phage display bank and a system for their optimization.
| FactSnippet No. 1,602,190 |
11.
MorphoSys' OkapY technology is a new proprietary “2+1” bispecific antibody format with the hysicochemical properties to simplify the development and large-scale production of such molecules.
| FactSnippet No. 1,602,191 |